<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995588</url>
  </required_header>
  <id_info>
    <org_study_id>Sclero-LTI</org_study_id>
    <nct_id>NCT04995588</nct_id>
  </id_info>
  <brief_title>Systemic Sclerosis and Innate T Cells</brief_title>
  <official_title>Role of Innate T Cells in Physiopathology of Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Innate T cells (ITC) are decreased in systemic sclerosis (SS) and an early lymphocyte&#xD;
      innateness has been reported. In the other part, ITC are implicated on inflammatory process,&#xD;
      including the IL-33/ST2 axis, which is also involved in ScS endotheliopathy.&#xD;
&#xD;
      Data are however scarce and physiopathological mechanisms have not been assessed to date.&#xD;
&#xD;
      The investigators hypothesize a global lymphocyte innateness in SSc, linked to a chronic ITC&#xD;
      stimulation by innate signals leading to ITC exhaustion, and their potential role in&#xD;
      endotheliopathy and fibroblast activation in SSc.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Basal numeration of circulating ITC (iNKT, MAIT, γδ-T and innate CD8(+) T-cells)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Percentage AND absolute count of iNKT, MAIT, γδ-T and innate CD8(+) T- cells in flow cytometry among total T cells in SSc patients (n=60), patients with other connective tissue disease (systemic lupus erythematosus, rheumatoid arthritis, primary Sjögren's syndrome, idiopathic inflammatory myopathies) (n=60), and in healthy subjects (n=60)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Basal expression level of Ki67 among circulating ITC (iNKT, MAIT, γδ-T and innate CD8(+) T-cells)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Percentage of iNKT, MAIT, γδ-T and innate CD8(+) T-cells expressing Ki67 in flow cytometry in SSc patients (n=60), patients with other connective tissue disease (systemic lupus erythematosus, rheumatoid arthritis, primary Sjögren's syndrome, idiopathic inflammatory myopathies) (n=60), and in healthy subjects (n=60)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Basal expression level of PLZF AND Eomes AND T-bet AND Helios of circulating ITC (iNKT, MAIT, γδ-T and innate CD8(+) T-cells)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Percentage of iNKT, MAIT, γδ-T and innate CD8(+) T-cells expressing PLZF, Eomes, T-bet and Helios in flow cytometry in SSc patients (n=60), patients with other connective tissue disease (systemic lupus erythematosus, rheumatoid arthritis, primary Sjögren's syndrome, idiopathic inflammatory myopathies) (n=60), and in healthy subjects (n=60)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Basal expression of perforin AND granzyme A among circulating ITC (iNKT, MAIT, γδ-T and innate CD8(+) T-cells)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Percentage of iNKT, MAIT, γδ-T and innate CD8(+) T-cells expressing perforin and granzyme A in flow cytometry in SSc patients (n=60), patients with other connective tissue disease (systemic lupus erythematosus, rheumatoid arthritis, primary Sjögren's syndrome, idiopathic inflammatory myopathies) (n=60), and in healthy subjects (n=60)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IFN-ɣ, IL-4 and IL-17 production of iNKT, MAIT, γδ-T and innate CD8(+) T-cells in response to IL-1, IL-8, IL-12, IL-18, IL-33 and fractalkine</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Percentage of iNKT, MAIT, γδ-T and innate CD8(+) T-cells expressing IFN-ɣ AND IL-4 AND IL-17 in flow cytometry upon stimulation by various combinations of IL-1, IL-8, IL-12, IL-18, IL-33 and fractalkine in SSc patients (n=60), patients with other connective tissue disease (systemic lupus erythematosus, rheumatoid arthritis, primary Sjögren's syndrome, idiopathic inflammatory myopathies) (n=60), and in healthy subjects (n=60)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Blood test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Unique blood test for all the participants included in the study to constitute a local biobank to assess in a grouped manner the prespecified outcomes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Unique blood draw of 45mL for all the participants</description>
    <arm_group_label>Blood test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  SSc according to the 2013 ACR/EULAR 2013 criteria (or the 2001 Leroy's criteria for&#xD;
             early SSc)&#xD;
&#xD;
          -  Patients with others connective tissue disease:&#xD;
&#xD;
               -  Systemic erythematosus lupus (SLE) according to the 2019 ACR/EULAR criteria&#xD;
&#xD;
               -  Primary Sjögren syndrome (pSS) according to the 2016 ACR/EULAR criteria&#xD;
&#xD;
               -  Rheumatoid arthritis according to the 2010 ACR/EULAR criteria&#xD;
&#xD;
               -  Idiopathic inflammatory myopathy (IIM) according to the 2017 ACR/EULAR criteria&#xD;
&#xD;
          -  Healthy subjects from general population without known autoimmune disease or&#xD;
             connective tissue disease&#xD;
&#xD;
          -  ≥18 years-old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Overlap syndrome (including secondary Sjögren syndrome)&#xD;
&#xD;
          -  Weight &lt;55 kgs&#xD;
&#xD;
          -  Known primary cell immunodeficiency&#xD;
&#xD;
          -  Immunosuppressive drug in the past 3 months (hydroxychloroquine and glucocorticoids&#xD;
             ≤7.5mg/d allowed)&#xD;
&#xD;
          -  Biotherapy in the past 6 months&#xD;
&#xD;
          -  Past of autologous or allogenic hematopoietic stem cell transplantation&#xD;
&#xD;
          -  Solid neoplasia or malignant hemopathy in remission for less than 12 months an&#xD;
&#xD;
          -  Chemotherapy and/or immune checkpoint inhibitors in the last 12 months&#xD;
&#xD;
          -  Systemic retinoids&#xD;
&#xD;
          -  Active infection and/or antibiotics in the last 2 weeks&#xD;
&#xD;
          -  Known active chronic infection among HIV, HTLV, viral hepatitis, syphilis&#xD;
&#xD;
          -  Vaccination in the last 4 weeks&#xD;
&#xD;
          -  Subject refusing genetic analysis for the present study&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mickaël MARTIN, MD, PhD</last_name>
    <phone>+33549444004</phone>
    <email>mickael.martin@chu-poitiers.fr</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

